tetano
Editor, Senior Moderator
Crit Rev Microbiol
. 2020 Oct 7;1-14.
doi: 10.1080/1040841X.2020.1822279. Online ahead of print.
Making a case for using γδ T cells against SARS-CoV-2
Mahboubeh Yazdanifar[SUP] 1 [/SUP], Narges Mashkour[SUP] 2 [/SUP], Alice Bertaina[SUP] 1 [/SUP]
Affiliations
Abstract
Intensive worldwide efforts are underway to determine both the pathogenesis of SARS-CoV-2 infection and the immune responses in COVID-19 patients in order to develop effective therapeutics and vaccines. One type of cell that may contribute to these immune responses is the γδ T lymphocyte, which plays a key role in immunosurveillance of the mucosal and epithelial barriers by rapidly responding to pathogens. Although found in low numbers in blood, γδ T cells consist the majority of tissue-resident T cells and participate in the front line of the host immune defense. Previous studies have demonstrated the critical protective role of γδ T cells in immune responses to other respiratory viruses, including SARS-CoV-1. However, no studies have profoundly investigated these cells in COVID-19 patients to date. γδ T cells can be safely expanded in vivo using existing inexpensive FDA-approved drugs such as bisphosphonate, in order to test its protective immune response to SARS-CoV-2. To support this line of research, we review insights gained from previous coronavirus research, along with recent findings, discussing the potential role of γδ T cells in controlling SARS-CoV-2. We conclude by proposing several strategies to enhance γδ T cell's antiviral function, which may be used in developing therapies for COVID-19.
Keywords: COVID-19; SARS-CoV-2; coronavirus; immune response; γδ T cell.
. 2020 Oct 7;1-14.
doi: 10.1080/1040841X.2020.1822279. Online ahead of print.
Making a case for using γδ T cells against SARS-CoV-2
Mahboubeh Yazdanifar[SUP] 1 [/SUP], Narges Mashkour[SUP] 2 [/SUP], Alice Bertaina[SUP] 1 [/SUP]
Affiliations
- PMID: 33023358
- DOI: 10.1080/1040841X.2020.1822279
Abstract
Intensive worldwide efforts are underway to determine both the pathogenesis of SARS-CoV-2 infection and the immune responses in COVID-19 patients in order to develop effective therapeutics and vaccines. One type of cell that may contribute to these immune responses is the γδ T lymphocyte, which plays a key role in immunosurveillance of the mucosal and epithelial barriers by rapidly responding to pathogens. Although found in low numbers in blood, γδ T cells consist the majority of tissue-resident T cells and participate in the front line of the host immune defense. Previous studies have demonstrated the critical protective role of γδ T cells in immune responses to other respiratory viruses, including SARS-CoV-1. However, no studies have profoundly investigated these cells in COVID-19 patients to date. γδ T cells can be safely expanded in vivo using existing inexpensive FDA-approved drugs such as bisphosphonate, in order to test its protective immune response to SARS-CoV-2. To support this line of research, we review insights gained from previous coronavirus research, along with recent findings, discussing the potential role of γδ T cells in controlling SARS-CoV-2. We conclude by proposing several strategies to enhance γδ T cell's antiviral function, which may be used in developing therapies for COVID-19.
Keywords: COVID-19; SARS-CoV-2; coronavirus; immune response; γδ T cell.